Treatment Of Prion Diseases
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsSahar Gelfman, Andreja Avbersek, Sarah Wolf, Alicia Hawes, Giovanni Coppola, Vijay Kumar Manickavasagam Pounraja
Life of this patent
Estimating the term…
Abstract
Methods of treating subjects having a prion disease or at risk of developing a prion disease by administering a nucleic acid molecule encoding a modified Prion protein (PrP), and methods of identifying a subject that is a candidate for treatment or prevention of a prion disease are presented herein.
Claims38
A method of treating a subject having a prion disease or at risk of developing a prion disease, the method comprising:
- a) administering a nucleic acid molecule encoding a modified Prion protein (PrP) to the subject;
- or
- b) administering an inhibitory nucleic acid molecule that that targets a region of a prion nucleic acid molecule (PRNP) that comprises a genetic variation that causes production of a scrapie PrP to the subject;
- wherein the subject comprises at least one reference PRNP allele or comprises at least one PRNP allele encoding an endogenous scrapie PrP;
- wherein the nucleic acid molecule encoding the modified PrP administered to the subject comprises a nucleotide sequence encoding PrP but having a deletion that comprises 24 nucleotides within the nucleotide sequence encoding the octapeptide repeat region.
10-11. (canceled)
13-15. (canceled)
17-19. (canceled)
A method of treating a subject having a prion disease or at risk of developing a prion disease by administering a nucleic acid molecule encoding a modified Prion protein (PrP) to the subject, the method comprising:
- determining or having determined whether the subject comprises at least one reference PRNP allele or comprises at least one PRNP allele encoding an endogenous scrapie PrP, by:
- obtaining or having obtained a biological sample from the subject;
- and
- performing or having performed a sequence analysis on the biological sample to determine if the subject has a genotype comprising at least one reference PRNP allele or comprising at least one PRNP allele encoding an endogenous scrapie PrP;
- and
- administering or continuing to administer the nucleic acid molecule encoding the modified PrP to the subject that has at least one reference PRNP allele or has at least one PRNP allele encoding an endogenous scrapie PrP;
- wherein the nucleic acid molecule encoding the modified PrP administered to the subject comprises a nucleotide sequence encoding PrP but having a deletion that comprises 24 nucleotides within the nucleotide sequence encoding the octapeptide repeat region;
- and
- wherein the presence of at least one reference PRNP allele or at least one PRNP allele encoding an endogenous scrapie PrP indicates the subject has an increased risk of developing a prion disease compared to a subject that is homozygous for a PRNP allele encoding PrP but having a deletion that comprises 24 nucleotides within the nucleotide sequence encoding the octapeptide repeat region.
29-30. (canceled)
32-34. (canceled)
36-38. (canceled)
A method of identifying a subject that is a candidate for treatment or prevention of a prion disease, the method comprising:
- determining or having determined whether the subject comprises at least one reference PRNP allele or comprises at least one PRNP allele encoding an endogenous scrapie PrP, by:
- obtaining or having obtained a biological sample from the subject;
- and
- performing or having performed a sequence analysis on the biological sample to determine if the subject has a genotype comprising at least one reference PRNP allele or comprising at least one PRNP allele encoding an endogenous scrapie PrP;
- and
- wherein the presence of at least one reference PRNP allele or at least one PRNP allele encoding an endogenous scrapie PrP indicates the subject has an increased risk of developing a prion disease compared to a subject that is homozygous for a PRNP allele encoding PrP but having a deletion that comprises 24 nucleotides within the nucleotide sequence encoding the octapeptide repeat region, and is a candidate for treatment or prevention.
44-46. (canceled)
48-58. (canceled)
A nucleic acid molecule encoding a modified Prion protein (PrP) that comprises a nucleotide sequence encoding PrP but having a deletion that comprises 24 nucleotides within the nucleotide sequence encoding the octapeptide repeat region.
60-75. (canceled)
Dependencies are inferred from the claim text.